Author Interviews, Heart Disease, JAMA / 15.01.2020
Newer Heart Pumps Help Patients Even If They Are Not Eligible for Heart Transplant
MedicalResearch.com Interview with:
[caption id="attachment_47945" align="alignleft" width="200"]
Dr. Mehra[/caption]
Mandeep R. Mehra, MD, MSc, FRCP
The William Harvey Distinguished Chair in
Advanced Cardiovascular Medicine
Medical Director, Heart and Vascular Center
Brigham and Women’s Hospital
Executive Director
Center for Advanced Heart Disease
Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
MedicalResearch.com: What is the background for this study?
Response: Left Ventricular assist devices meaningfully prolong survival in patients with heart failure who are no longer responsive to guideline-directed medications.
The MOMENTUM 3 trial tested a new generation device, the HeartMate 3 pump, to a more commonly used pump, the HeartMate II device. This trial showed the superiority of the new heart pump and found that survival free of a disabling stroke or need to place a second pump is improved considerably.
In this prespecified analysis of the trial, we compared patients who were considered as eligible for transplantation to those considered ineligible for heart transplantation. We showed that these categories are associated with similar superiority of the HeartMate 3 pump compared to the control pump despite the categorization into these discrete buckets.
Dr. Mehra[/caption]
Mandeep R. Mehra, MD, MSc, FRCP
The William Harvey Distinguished Chair in
Advanced Cardiovascular Medicine
Medical Director, Heart and Vascular Center
Brigham and Women’s Hospital
Executive Director
Center for Advanced Heart Disease
Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
MedicalResearch.com: What is the background for this study?
Response: Left Ventricular assist devices meaningfully prolong survival in patients with heart failure who are no longer responsive to guideline-directed medications.
The MOMENTUM 3 trial tested a new generation device, the HeartMate 3 pump, to a more commonly used pump, the HeartMate II device. This trial showed the superiority of the new heart pump and found that survival free of a disabling stroke or need to place a second pump is improved considerably.
In this prespecified analysis of the trial, we compared patients who were considered as eligible for transplantation to those considered ineligible for heart transplantation. We showed that these categories are associated with similar superiority of the HeartMate 3 pump compared to the control pump despite the categorization into these discrete buckets.
Dr. Breyer[/caption]
Benjamin N. Breyer MD, MAS, FACS
Associate Professor
Departments of Urology and Epidemiology and Biostatistics
University of California, San Francisco
Vice-Chair of Urology
Chief of Urology, Zuckerberg San Francisco General Hospital and Trauma Center
Director, UCSF Male Genitourinary Reconstruction and Trauma Surgery Fellowship
MedicalResearch.com: What is the background for this study?
Response: There has been a large increase in upright scooter usage among adults as a mode of transportation. It's convenient for commuters and may encourage greater use of public transit leading to less car traffic in cities.
Dr. Anderson[/caption]
MedicalResearch.com Interview with:
Matilda Anderson MBBS MBS
General Surgery Trainee/Public Health/Researcher
Footscray, Victoria, Australia
MedicalResearch.com: What is the background for this study?
Response: Female representation in the surgical workforce is increasing. Previous studies have shown higher infertility rates and adverse pregnancy outcomes in this population. We aimed to accurately define the available research in this area and provide some basic recommendations about how workplaces can support their female surgical residents and surgeons.
On a more personal note- Dr Anderson is a female surgical resident and have seen countless pregnant colleagues remove themselves from operating rooms with the concern about how the conditions may affect their pregnancies. Dr. Anderson met Associate Professor Goldman at Harvard University (a leading expert on occupational reproductive hazards) and collaborated to explore this area further.
Dr. Cohen[/caption]
Pieter A. Cohen, MD
Department of Medicine, Cambridge Health Alliance
Somerville, Massachusetts
Harvard Medical School
Boston, Massachusetts
MedicalResearch.com: What is the background for this study?
Response: There has been increasing interest in the use of over-the-counter supplements to help improve memory and cognitive function. However, prior
Dr. Ritch[/caption]
Robert Ritch, MD, FACS, FARVO
Shelley and Steven Einhorn Distinguished Chair
Professor of Ophthalmology, Surgeon Director Emeritus
Chief, Glaucoma Services Emeritus
The New York Eye and Ear Infirmary of Mount Sinai
New York, NY 10003
Founder, Medical Director and
Chairman, Scientific Advisory Board
The Glaucoma Foundation
MedicalResearch.com: What is the background for this study?
Response: Nailfold capillaroscopy (NFC), long used in rheumatology is a new approach to investigation of glaucoma.
Posterior to the nailbed and just anterior to the proximal nailfold is the cuticle, which has no structural elements visible to the naked eye. NFC is a non-invasive imaging modality that provides a highly magnified view of the capillaries at the nailfold of digits. It has also been used in ophthalmology to show morphological changes at the nailfold capillaries of POAG and XFG/XFS patients, helping to confirm the systemic nature of these diseases.
[caption id="attachment_52469" align="alignleft" width="400"]
Dr. Emily Parker Hyle[/caption]
Emily Parker Hyle, M.D.
Assistant Professor of Medicine
Massachusetts General Hospital
MedicalResearch.com: What is the background for this study?
Response: We found that many children who were planning to travel internationally were eligible for MMR vaccination prior to departure but often did not receive it - especially if they were aged 6 months to 6 years. That is because most children do not routinely receive their first dose of MMR till 12-15 months of age and their second dose of MMR till 4-6 years of age. However, ACIP recommendations are different for children who are traveling internationally. The risk of being infected with measles is much higher outside of the US, so it is recommended that children older than 1 year have had 2 MMR vaccinations and that children 6-12 months receive 1 MMR vaccination prior to travel. MMR vaccination is a safe and effective way to greatly reduce the risk of measles infection.